Lawsuit-laden J&J recalls baby powder after asbestos alertJohnson & Johnson has said it is recalling around 33,000 bottles of baby powder in the US, after Share XLawsuit-laden J&J recalls baby powder after asbestos alerthttps://pharmaphorum.com/news/lawsuit-laden-jj-recalls-baby-powder-after-asbestos-alert/
Is the US opioid litigation nearing an end game?Drugmakers, wholesalers and lawmakers in the US are said to be thrashing out the details of a big Share XIs the US opioid litigation nearing an end game?https://pharmaphorum.com/news/is-the-us-opioid-litigation-nearing-an-end-game/
MSF calls for J&J to cut price of TB medicineThe humanitarian medical organisation Medecins Sans Frontieres (MSF) has called on Johnson & Johnson to cut the price Share XMSF calls for J&J to cut price of TB medicinehttps://pharmaphorum.com/news/msf-calls-for-jj-to-cut-price-of-tb-medicine/
J&J seeks wider use of its Spravato antidepressant in USJohnson & Johnson has filed for US approval for a new claim on the label for its nasal Share XJ&J seeks wider use of its Spravato antidepressant in UShttps://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/
J&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onJohnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, Share XJ&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onhttps://pharmaphorum.com/news/jj-settles-ohio-lawsuits-for-20m-as-opioid-litigation-train-rumbles-on/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
FDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallThe FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has Share XFDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallhttps://pharmaphorum.com/news/fda-approves-jjs-prostate-cancer-drug-erleada-in-new-use-as-zytiga-sales-fall/
J&J filing aims Tremfya at crowded psoriatic arthritis marketJohnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, Share XJ&J filing aims Tremfya at crowded psoriatic arthritis markethttps://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialJohnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio Share XJanssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialhttps://pharmaphorum.com/news/janssens-ms-pill-outshines-sanofis-aubagio-in-phase-3-trial/
